Mutations in LRRK2 are the most common cause of familial Parkinson’s disease. This work supports a protective role of LRRK2 kinase inhibition in G2019S carriers and provides a workflow for systematic evaluation of brain-wide phenotypes
Code to reproduce network analyses and a-synuclein pathology progression plots in "Molecular analysis of network vulnerability to α-synuclein pathology reveals PAKs as therapeutic targets for Parkinson's disease".
This repository is intended to reproduce the model simulations and figure-generation workflows associated with the manuscript. Initial public release of the model code and documentation for the Belal et al. 2026 study.